At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
We came to Biogen to solve the unsolvable. We stay to create new possibilities and grow together. We work fearlessly and go beyond because we care deeply about making a difference and changing lives. All legitimate correspondence from a Biogen employee will come from “@biogen.com” or “@smartrecruiters.com” email accounts.
Dedication to Scientific Discovery: A COVID-19 Update on R&D as of May 21, 2020
At Biogen, our dedication to science and discovery has never been more important than it is today. We, of course, remain laser focused on our work as a leading neuroscience company, but we’re also finding meaningful ways to be part of the fight against COVID-19 – by leveraging our people’s knowledge, talent and experience, and resources to support research efforts.
Consortium with Broad Institute and Partners HealthCare
Together with the Broad Institute of MIT and Harvard, and Partners HealthCare, we announced a consortium that will build and share a COVID-19 biobank. The biobank will help scientists study a large collection of de-identified biological and medical data to advance knowledge and search for potential vaccines and treatments. Biogen employees and family members who have recovered from COVID-19, as well as their close contacts, can voluntarily contribute blood samples and medical data to aid efforts to help understand the disease with the ultimate goal of overcoming it.
Building on our Expertise
In March, infectious disease company Vir Biotechnology announced its intent to enter into an agreement for cell line development, process development and clinical manufacturing with Biogen. Vir is working on an antibody which, they believe, can potentially bind to COVID-19 – potentially preventing or treating the infection in the future. By seeking to combine Biogen’s technical development and manufacturing process capabilities with Vir’s monoclonal antibodies, Vir is working to advance the development of potential therapies.
Supporting Interferon Experimentation
Recently, the World Health Organization (WHO) announced a SOLIDARITY trial that, among other medicines, will assess the use of antiviral drugs and interferon as a potential treatment for COVID-19. We have reached out to the WHO to discuss how we might support these efforts.
Moving forward, we aim to strike a balance between contributing to COVID-19 research efforts and continuing to deliver on our important work to tackle devastating neurological diseases. It has never been more critical that we stay focused on furthering the science and serving patients around the world. Our people are committed to this important work.
View all COVID-19 updates
You are now leaving Biogen’s corporate website.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.